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Gleason grading is the best independent predictor for prostate cancer (PCa) progres-
sion. Recently, a new PCa grading system has been introduced by the International 
Society of Urological Pathology (ISUP) and is recommended by the World Health 
Organization (WHO). Following studies observed more accurate and simplified grade 
stratification of the new system. Aim of this study was to compare the prognostic value 
of the new grade groups compared to the former Gleason Grading and to determine 
whether re-definition of Gleason Pattern 4 might reduce upgrading from prostate biopsy 
to radical prostatectomy (RP) specimen. A cohort of men undergoing RP from 2002 to 
2015 at the Hospital of Goeppingen (Goeppingen, Germany) was used for this study. In 
total, 339 pre-operative prostatic biopsies and corresponding RP specimens, as well as 
additional 203 RP specimens were re-reviewed for Grade Groups according to the ISUP. 
Biochemical recurrence-free survival (BFS) after surgery was used as endpoint to analyze 
prognostic significance. Other clinicopathological data included TNM-stage and pre- 
operative PSA level. Kaplan–Meier analysis revealed risk stratification of patients based 
on both former Gleason Grading and ISUP Grade Groups, and was statistically significant 
using the log-rank test (p < 0.001). Both grading systems significantly correlated with 
TNM-stage and pre-operative PSA level (p < 0.001). Higher tumor grade in RP speci-
men compared to corresponding pre-operative biopsy was observed in 44 and 34.5% 
of cases considering former Gleason Grading and ISUP Grade Groups, respectively. 
Both, former Gleason Grading and ISUP Grade Groups predict survival when applied 
on tumors in prostatic biopsies as well as RP specimens. This is the first validation 
study on a large representative German community-based cohort to compare the former 
Gleason Grading with the recently introduced ISUP Grade Groups. Our data indicate 
that the ISUP Grade Groups do not improve predictive value of PCa grading and might 
be less sensitive in deciphering tumors with 3 + 4 and 4 + 3 pattern on RP specimen. 
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However, the Grade Group system results less frequently in an upgrading from biopsy to 
the corresponding RP specimens, indicating a lower risk to miss potentially aggressive 
tumors not represented on biopsies.
Keywords: prostate cancer, gleason score, international society of Urological Pathology grade groups, 
prognostic biomarker, cancer grading
inTrODUcTiOn
Prostate cancer (PCa) is the most common cancer type among 
men worldwide accounting for more than 20% of all newly 
diagnosed cancers (1). Patients show a highly variable course of 
disease, resulting in a major challenge for clinical management 
(2). Consequently, it is of utmost importance to stratify patients 
with early-stage disease into certain risk groups, predicting 
the probability of remaining an indolent or progressing to an 
aggressive form of PCa. In addition to clinical stage and serum 
PSA level, Gleason grading of the tumor is a powerful prognos-
tic marker at time point of diagnosis and has major impact on 
therapy decision (3). A limitation of Gleason grading is upgrad-
ing from biopsy to radical prostatectomy (RP) specimens, most 
often in lower grade tumors, which is associated with worse 
outcome of patients (4). In addition, considerable interobserver 
variability limits PCa grading to be reproducible in a subset of 
cases (5).
Since its introduction (6), the Gleason Grading system has 
undergone several revisions in order to improve reproducibility 
and prognostic value (7). Most recently, a new grading system 
has been proposed by the International Society of Urological 
Pathology (ISUP) (8) and is integrated into the 2016 edition 
of the WHO classification of Tumor of the Urinary System 
and Male Genital Organs (9). Major modifications of the ISUP 
Grade Groups toward the last update in 2010 include defining 
five distinct Grade Groups based on the Gleason score: Grade 
Group 1 = Gleason score ≤6, Grade Group 2 = Gleason score 
3 +  4 =  7, Grade Group 3 =  Gleason score 4 +  3 =  7, Grade 
Group 4 = Gleason score 8, Grade Group 5 = Gleason scores ≥9, 
as well as modified morphological criteria for Gleason pattern 4 
(9). Consequently, various growth patterns, including ill-formed, 
fused, cribriform, and glomeruloid glands are considered as 
Gleason grade 4 tumors. In consideration of a multi-institutional 
validation study (10), the ISUP Grade Groups emerged as more 
accurate and simplified classification to stratify tumors than the 
current system (9).
A number of recently published studies independently 
validated the ISUP Grade Groups as prognostic marker for 
bio chemical recurrence (BR) as well as disease-specific death of 
patients (11–14). While some observed prognostic benefits of 
the new classification, others reported no significant difference 
to the former Gleason Grading (12, 15). It has to be consid-
ered that the mentioned studies vary regarding end points for 
survival analysis and treatment strategies of patients, resulting 
in limited comparability.
The aim of our study was to compare the prognostic value 
as well as the frequency of upgrading from diagnostic biopsy 
to RP specimen between the former Gleason Grading and the 
ISUP Grade Groups. Diagnostic biopsies and RP specimens were 
re-reviewed and graded according to the new classification.
MaTerials anD MeThODs
A cohort including 339 prostatic pre-operative biopsies and 
corresponding RP specimens, as well as additional 203 RP 
specimens from patients who were treated between 2002 and 
2015 at the Hospital of Goeppingen (Goeppingen, Germany) 
was used for the present study. Only biopsies from patients who 
achieved subsequent RP were included for survival analyses. All 
RP specimens and biopsies were initially graded by pathologists 
of the Hospital of Goeppingen, and afterward re-graded in a cen-
tralized manner by an expert GU pathologist according to the 
current ISUP grading system. BR was defined as postoperative 
PSA increase of ≥0.2 ng/ml. Patients’ characteristics are sum-
marized in Table 1.
Ethical approval for using human material in this study was 
obtained from the Internal Review Board of the University Hos-
pital of Bonn (264/11). The study participants were anonymized 
before their specimens were included to this retrospective 
study cohort.
Chi-square tests were used for comparison of BR between 
the former Gleason Grading and the ISUP Grade Groups as 
categorical variables. To analyze univariable differences in 
BFS between the former Gleason Grading and the ISUP Grade 
Groups, the log-rank test was used. Kaplan–Meier curves 
illustrate BFS after treatment stratified by the former Gleason 
Grading and the ISUP Grade Groups. Multivariable Cox 
proportional hazards models were performed to identify inde-
pendent prognostic factors. Grading on biopsies were adjusted 
for the log of pre-operative PSA (≤/> 10 ng/ml), and grading 
on RP specimens were adjusted for the log of pre-operative PSA 
(≤/> 10 ng/ml), pathological T-stage (pT2, pT3a, pT3b, pT4), 
lymph node status (pN0, pN1), and surgical margin status (pR0, 
pR1). Gleason Score 3  +  3 and Grade Group 1 were used as 
reference group for hazard ratios.
All statistics were done with SPSS vers. 2.0 (Inc., Chicago, 
IL, USA).
Study design, patient characteristics, methods, and statistical 
analysis as well as data presentation and discussion have been 
performed according to the REMARK (REporting recommen-
dations for tumor MARKer prognostic studies) guidelines (16).
resUlTs
Biochemical recurrence-free survival was used as end point 
to compare prognostic value of different grading systems. The 
Table 2 | Association between different grading systems at RP or diagnostic 
biopsies and frequency of biochemical recurrence (BR).
br [n (%)] p-Value
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Table 1 | Baseline characteristics of patients.
Median (range) preoperative PSA (ng/ml) 7.35 (0.0–3202.0)
Preoperative Psa
<10 ng/ml [n (%)] 383 (70.9)
>10 ng/ml [n (%)] 157 (29.1)





Extraprostatic tumor expansion [n (%)] 165 (32.2)
lymph node status [n (%)]
N0 492 (90.8)
N1 50 (9.2)
surgical margin [n (%)]
pR0 413 (76.2)
pR1 129 (23.8)
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risk stratification of patients over time (log-rank test  <  0.001) 
(Figures 1A,B and 2A,B). Concordantly, higher former Gleason 
Grade and ISUP Grade Group associates with lower 5-year-BFS 
rates of patients (Figures  1C and 2C). The 5-year-BFS rate of 
tumors graded with former Gleason Score 3 + 3 on RP (91.4%) 
as well as biopsies (80.6%) was lower compared to tumors 
graded with ISUP Grade Group 1 (94.9% at RP, 88.8% at biopsy). 
By contrast, 5-year-BFS rate of ISUP Grade Group 2 (74.2%) and 
ISUP Grade Group 3 (41%) tumors at RP were higher compared 
to tumors graded with former Gleason Score 3 + 4 (48.3%) and 
4 + 3 (37.2%). Kaplan–Meier curve shows higher cumulative BFS 
and 5-year BFS rate of patients with ISUP Grade Group 4 tumors 
compared to ISUP Grade Group 3 tumors (Figures 1B,C).
Using former Gleason Score 3 + 3 and ISUP Grade group 1 
as reference group in multivariable Cox analysis, RP specimens 
with former Gleason Score (ISUP Grade group) 3 + 4 (2), 4 + 3 
(3), 8 (4), >9 (5) are associated with 1.78 (4.08), 4.81 (10.25), 6.53 
(7.81) and 6.57 (12.93) times increased hazard for BR, respec-
tively (Table 3). When determined at diagnostic biopsies, former 
Gleason Score (ISUP Grade group) 3 + 4 (2), 4 + 3 (3), 8 (4), 
>9 (5) is associated with 2.07 (3.25), 3.55 (3.98), 4.55 (4.93), and 
7.11 (9.40) times increased hazard for BR, respectively (Table 4). 
In multivariate analyses, RP specimens were adjusted to lymph 
node status, surgical margin status, T-stage, and pre-operative 
PSA (Table  3), and biopsies to pre-operative PSA (Table  4). 
In multivariate analysis, RP specimens graded as 3  +  4 by the 
former Gleason Grading is associated with 1.78 times increased 
hazard for BR referring to 3 + 3 tumors which is statistically not 
significant (0.058) (Table 3). Collectively, hazard ratios for BR are 
higher for tumors graded by the ISUP Grade Groups compared to 
the former Gleason Grading.
frequency of BR at any time point after treatment increases with 
both rising former Gleason Grading and ISUP Grade Groups as 
assessed on RP specimens as well as diagnostic biopsies (Table 2). 
The rate of BR of tumors graded with 3 + 3 on RP (9.2%) as well 
as biopsies (21.4%) was higher compared to tumors graded with 
Grade Group 1 (5.9% at RP, 13.7% at biopsy). In RP specimens, 
we observed lower frequency of BR in Grade Group 4 tumors 
(42.9%) compared to Grade Group 3 tumors (53.7%), but clearly 
higher and lower rate compared to Grade Group 2 (23.1%) and 
Grade Group 5 (71.9) tumors, respectively (Table 2). Statistical 
analysis revealed significant association between both, the for-
mer Gleason Grading and the ISUP Grade Groups, and risk for 
BR (Chi-Square, p < 0.001) (Table 2).
Kaplan–Meier curves illustrate reduced cumulative BFS time 
in tumors with higher former Gleason Grading and ISUP Grade 
Groups at both, RP and diagnostic biopsy, allowing significant 
A B
C
FigUre 1 | Kaplan–Meier analysis for biochemical recurrence free survival (BFS) according to the former Gleason Grading and International Society of Urological 
Pathology (ISUP) Grade Groups on RP specimens. (a) Biochemical recurrence-free survival (BFS) stratified by Gleason ≤6, Gleason 3 + 4, Gleason 4 + 3, Gleason 
8 and Gleason ≥9. (b) BFS stratified by Grade Group 1, Grade Group 2, Grade Group 3, Grade Group 4, and Grade Group 5. (c) 5-year BFS rate in % for grading 
according to former Gleason Grading or ISUP Grade Group.
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Overall, in nine patients, disease recurrences appeared as 
local tumor recurrence or development of distant metastases 
(assigned as clinical recurrence), partially after diagnosis of BR. 
Only 6 patients died from PCa. Association between different 
grading systems and clinical recurrence and disease-specific 
death are listed in Table 2.
Both the former Gleason Grading and the ISUP Grade Groups 
significantly correlate with T-stage, lymph node status and pre-
operative PSA level (Chi-square p < 0.001).
Upgrading from diagnostic biopsy to RP specimen occurred 
in 34.5% considering ISUP Grade Groups, and more often 
considering the former Gleason Grading (44.0%) (Table 3). The 
vast majority of cases affected low grade tumors independent of 
the grading system. Frequency and distribution of upgrading are 
listed in Table 5.
DiscUssiOn
Collectively, our findings confirm that the recently introduced 
ISUP Grade Groups independently predicts BR after treatment 
when conducted on both, RP specimens and diagnostic biop-
sies. Thus, these data support previous suggestions of the ISUP 
meeting 2014 to include ISUP Grade Groups into pathology 
reports (9).
Patients with low-risk disease are constantly risk stratified 
as tumors on diagnostic biopsies with ISUP Grade Group 
2, 3, 4, and 5 exhibited a 3.25, 3.98, 4.93, and 9.40 hazard 
increased risk for BR compared to ISUP Grade Group 1 tumors, 
respectively (Table  4). Importantly, therapy decision is made 
based on the grading of diagnostic biopsies, PSA blood level, 
clinical tumor stage, and individual factors. With the objective 
to avoid over-treatment of indolent PCa, alternative regimes 
such as active surveillance and watchful waiting are increas-
ingly applied worldwide (17). Among others, criteria for active 
surveillance include Gleason Score ≤6 in biopsy specimens 
to select patients with potential low-risk disease (18). Based 
on our results showing a 5-year BFS rate of 88.8% in ISUP 
Grade Group 1 biopsies, the recently introduced ISUP Grade 
Groups are sensitive markers to identify low-risk patients 
who should not undergo radical treatment approaches. In our 
evaluation, the ISUP Grade Groups emerged as even more 
sensitive compared to the former Gleason Grading (5-year 




FigUre 2 | Kaplan–Meier analysis for biochemical recurrence free survival (BFS) according to the former Gleason Grading and International Society of Urological 
Pathology (ISUP) Grade Groups on diagnostic biopsies. (a) BFS stratified by Gleason ≤6, Gleason 3 + 4, Gleason 4 + 3, Gleason 8, and Gleason ≥9. (b) BFS 
stratified by Grade Group 1, Grade Group 2, Grade Group 3, Grade Group 4, and Grade Group 5. (c) 5-year BFS rate in% for grading according former Gleason 
Grading or ISUP Grade Group.
Table 3 | Multivariate Cox analysis for biochemical recurrence free survival 
(BFS) according to different grading systems on RP specimens (HR = hazard 
ratio, CI = confidence interval, RP = radical prostatectomy).
clinicopathological parameter Multivariate analysis
 hr (95% ci) p-Value
Former gleason score [n (%)]  
at radical prostatectomy (rP)
≤6
3 + 4 1.78 (0.98–3.22) 0.058
4 + 3 4.81 (2.47–9.38) <0.001
8 6.53 (3.53–12.05) <0.001
≥9 6.57 (3.34–12.91) <0.001
international society of Urological 
Pathology grade group [n (%)] at rP
1   
2 4.08 (2.04–8.17) <0.001
3 10.25 (5.01–20.96) <0.001
4 7.81 (3.51–17.36) <0.001
5 12.93 (5.70–29.31) <0.001
Table 4 | Multivariate Cox analysis for Biochemical recurrence-free survival 
(BFS) according to different grading systems on biopsies (HR = hazard ratio, 
CI = confidence interval, RP = radical prostatectomy).
clinicopathological parameter Multivariate analysis
hr (95% ci) p-Value
Fomer gleason score [n (%)] at 
diagnostic biopsy
≤6   
3 + 4 2.07 (1.31–3.26) 0.002
4 + 3 3.55 (1.6–7.92) 0.002
8 4.55 (2.13–9.73) <0.001
≥9 7.11 (2.19–23.13) 0.001
international society of Urological 
Pathology grade group [n (%)]  
at diagnostic biopsy
1  
2 3.25 (1.85–5.73) <0.001
3 3.98 (2.00–7.9) <0.001
4 4.93 (2.68–9.08) <0.001
5 9.40 (5.08–17.41) <0.001
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Various growth patterns, including ill-formed, fused, cri-
briform, and glomeruloid glands, are considered as Gleason 
grade 4 tumors in the ISUP Grade Groups (9). In general, 
diagnosis of Gleason pattern 4 is associated with the highest 
interobserver variability among pathologists. Evaluating the 
interobserver reproducibility of individual Gleason pattern 4, 
Table 5 | Frequency and distribution of upgrading from diagnostic biopsy to RP.
Upgrading from  
biopsy to rP
n (%) Upgrading from biopsy to rP n (%)
Former Gleason  
Score (total)
149 (44.0) International Society of Urological 
Pathology Grade Group (total)
117 (34.5)
≤6 → 3 + 4 75 (22.1) 1 → 2 74 (21.8)
≤6 → 4 + 3 13 (3.8) 1 → 3 12 (3.5)
≤6 → 4 + 4 18 (5.3) 1 → 4 5 (1.5)
≤6 → ≥ 9 8 (2.4) 1 → 5 1 (0.3)
3 + 4 → 4 + 3 8 (2.4) 2 → 3 10 (2.9)
3 + 4 → 4 + 4 9 (2.7) 2 → 4 3 (0.9)
3 + 4 → ≥ 9 7 (2.1) 2 → 5 2 (0.6)
4 + 3 → 4 + 4 2 (0.6) 3 → 4 4 (1.2)
4 + 3 → ≥ 9 3 (0.9) 3 → 5 2 (0.6)
4 + 4 → ≥ 9 6 (1.8) 4 → 5 4 (1.2)
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a recently published study concluded consensus on cribriform 
and glomeruloid patterns but lacking consensus on ill-formed 
and fused glands (18). While our re-evaluation of RP specimens 
significantly differentiates ISUP Grade Group 1, ISUP Grade 
Group 2, and ISUP Grade Group 3 tumors exhibiting BR rates 
of 5.9, 23.1, and 53.7%, respectively, results show reduced BR 
frequency of ISUP Grade Group 4 tumors (42.9%) (Table  2) 
and higher cumulative BFS (Figures 1B,C) compared to ISUP 
Grade Group 3 tumors. This observation might result from 
various factors, including modified definition of Gleason pat-
tern 4, partially suggesting to constitute a borderline pattern 
with reduced interobserver reproducibility (19). In addition, 
the proportion of ISUP Grade Group 4 tumors was relatively 
low accounting for 7.7% (42/542) of all RP specimens, resulting 
in limited informative value. Finally, general interobserver vari-
ability might have contributed to this discrepancy. Interestingly, 
a comparable observation has been made by Loeb et  al  (12), 
reporting a 4-year BFS rate of 77% for ISUP Grade Group 4 
on biopsy, and a slightly lower rate for ISUP Grade Group 3 
tumors (74%). Obviously, this result derives from grading on 
biopsies associated with upgrading to RP, and the discrepancy 
is marginal. However, overall data give evidence that separation 
Gleason pattern 3 from pattern 4 and reporting its proportion 
remains challenging.
Multiple studies revealed upgrading from diagnostic biopsy 
to corresponding RP specimen reporting incidences between 
14 and 51% with a mean of 36% (20). Major issues emerged 
during recent years as Gleason grading on diagnostic biopsy 
has significant impact on therapy decision at time point of 
diagnosis to select patients for surgery, radiation or active 
surveillance. Upgrading indicates potential undertreatment 
of patients with assumed low-risk disease and is associated 
with worse outcome (21). Several updates of the Gleason grad-
ing system such as reporting the most common and highest 
Gleason pattern on biopsy, re-defining pattern 4 as well as 
increasing the number of biopsies have been performed in 
order to improve its prediction accuracy and reduce upgrading 
(20). We observed upgrading from biopsy to corresponding RP 
specimen in 44.0% of cases considering the former Gleason 
Grading, and less common after re-grading according to the 
ISUP Grade Groups (34.5%) (Table  5). In accordance with 
published data, the vast majority of upgrading occurred from 
tumors with former Gleason Score ≤6 and ISUP Grade Group 
1, most often to former Gleason Score 3 + 4 and ISUP Grade 
Group 2 at RP (Table 5). Equal observation has been reported 
by a recently published study showing most frequent upgrades 
from biopsy ISUP Grade Group 1 to RP ISUP Grade Group 
2 (22). Collectively, our results give evidence that the modi-
fied definition of pattern 4 reduces upgrading, thus associates 
with improved predictive accuracy and lower risk of under 
treatment.
Since patients with highly aggressive disease are underrepre-
sented in our study, correlation between grading and important 
endpoints such as development of metastasis and PCa specific 
death is limited. As discussed above, ISUP Grade Group 4 was 
diagnosed in 7.7% of all RP, limiting statistical significance 
and informative value within this group. Furthermore, former 
Gleason Grading of biopsies and RP specimens was performed 
by pathologists from different institutes which might influence 
higher incidence of upgrading.
To conclude, our data support the previously accepted ISUP 
Grade Groups according to the ISUP meeting 2014 as independ-
ent prognostic marker for PCa. Diagnosis of Gleason pattern 4 
and distinguishing Grade Group 3 from Grade Group 4 remains 
challenging, considering limitations of this study and general 
interobserver variability. On RP specimens, we did not observe 
prognostic benefits of the ISUP Grade Groups compared to the 
former Gleason Grading. However, in our study the incidence 
of upgrading from biopsy to corresponding RP was lower by 
using the ISUP Grade Groups, giving evidence that the ISUP 
Grade Groups might improve predictive accuracy as assigned on 
diagnostic biopsies.
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